Philip J. Mease
Experienced in Systemic Sclerosis (SSc)

Dr. Philip J. Mease

Rheumatology
601 Broadway, 0, 
Seattle, WA 
Accepting New Patients
Offers Telehealth
45 Years of Experience
Experienced in Systemic Sclerosis (SSc)
601 Broadway, 0, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dr. Mease graduated from Stanford University receiving his Medical Doctorate. He specializes in internal medicine and rheumatology. Dr. Mease is a practicing physician at Seattle Rheumatology Associates, Swedish Cherry Hill, and Swedish First Hill.

Dr. Mease is rated as an Experienced provider by MediFind in the treatment of Systemic Sclerosis (SSc). His top areas of expertise are Psoriatic Arthritis, Arthritis, Psoriasis, and Axial Spondyloarthritis (AxSpA).

His clinical research consists of co-authoring 529 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Systemic Sclerosis (SSc).

Graduate Institution
Stanford Hospital And Clinics , 1977
Residency
University of Washington School of Medicine , 1980
Specialties
Rheumatology
Licenses
Internal Medicine in WA
Board Certifications
American Board Of Internal Medicine
Fellowships
University of Washington School of Medicine , 1982
Hospital Affiliations
Swedish Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Group Health Cooperative
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Lifewise

Accepted plan types not found. Please verify directly with the provider.

Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Regence
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
View 8 Less Insurance Carriers -

Locations

Seattle Rheumatology Associates
601 Broadway, 0, Seattle, WA
Other Locations
Swedish Cherry Hill
500 17th Avenue, Seattle, WA 98122
Swedish First Hill
747 Broadway, Seattle, WA 98122

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
CLassification of Axial SpondyloarthritiS Inception Cohort
CLassification of Axial SpondyloarthritiS Inception Cohort
Enrollment Status: Completed
Publish Date: December 08, 2022
Treatments Against RA and Effect on FDG-PET/CT (The TARGET Trial)
Treatments Against RA and Effect on FDG-PET/CT (The TARGET Trial)
Enrollment Status: Completed
Publish Date: October 26, 2022
Intervention Type: Drug
Study Drugs: Methotrexate, Sulfasalazine, Hydroxychloroquine, Etanercept, Adalimumab
Study Phase: Phase 4
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 3
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: March 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

528 Total Publications

Consensus definitions of complex-to-manage and treatment-refractory psoriatic arthritis: a GRAPPA initiative.
Consensus definitions of complex-to-manage and treatment-refractory psoriatic arthritis: a GRAPPA initiative.
Journal: Nature reviews. Rheumatology
Published: November 07, 2025
Similar Doctors
Distinguished in Systemic Sclerosis (SSc)
Dr. Jeffrey S. Carlin
Rheumatology
Distinguished in Systemic Sclerosis (SSc)
Dr. Jeffrey S. Carlin
Rheumatology

The Association Of University Physicians

1959 Ne Pacific St, 
Seattle, WA 
 (2.8 miles away)
206-598-4333
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Carlin is a Rheumatologist in Seattle, Washington. Dr. Carlin is rated as a Distinguished provider by MediFind in the treatment of Systemic Sclerosis (SSc). His top areas of expertise are Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA), Scleroma, and Scleroderma. Dr. Carlin is currently accepting new patients.

Distinguished in Systemic Sclerosis (SSc)
Dr. Gregory C. Gardner
Rheumatology
Distinguished in Systemic Sclerosis (SSc)
Dr. Gregory C. Gardner
Rheumatology

The Association Of University Physicians

1701 Columbia Rd, 
Seattle, WA 
 (2.7 miles away)
206-598-3100
Languages Spoken:
English, Castilian, Mandingo, Spanish, Swedish, Tamil
See accepted insurances
Accepting New Patients
Offers Telehealth

Gregory Gardner is a Rheumatologist in Seattle, Washington. Dr. Gardner is rated as a Distinguished provider by MediFind in the treatment of Systemic Sclerosis (SSc). His top areas of expertise are Lupus Nephritis, Takayasu Arteritis, Neurosarcoidosis, and Sarcoidosis. Dr. Gardner is currently accepting new patients.

Distinguished in Systemic Sclerosis (SSc)
Dr. Mark H. Wener
Allergy and Immunology | Rheumatology
Distinguished in Systemic Sclerosis (SSc)
Dr. Mark H. Wener
Allergy and Immunology | Rheumatology

The Association Of University Physicians

1959 Ne Pacific St, 
Seattle, WA 
 (2.8 miles away)
206-598-4333
Languages Spoken:
English, Castilian, Hindi, Russian, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Wener is an Allergy and Immunologist and a Rheumatologist in Seattle, Washington. Dr. Wener is rated as an Advanced provider by MediFind in the treatment of Systemic Sclerosis (SSc). His top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Relapsed Refractory Multiple Myeloma (RRMM), and Scleroma. Dr. Wener is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mease's expertise for a condition
ConditionClose
View All 8 Elite Conditions
    View All 15 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile